Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,116.17 +16.21 (+0.32%) Dow
38,386.09 +146.43 (+0.38%) Nasdaq
15,983.08 +55.18 (+0.35%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,276.16 -62.91 (-4.70%)
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
| Previous close | 6,297.10 |
| Open | 6,299.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6,185.00 - 6,313.00 |
| 52-week range | 4,384.05 - 6,505.90 |
| Volume | |
| Avg. volume | 385,252 |
| Market cap | 1.033T |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 19.78 |
| EPS (TTM) | 313.60 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | 40.00 (0.64%) |
| Ex-dividend date | 11 Jul 2023 |
| 1y target est | 5,909.41 |
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
Business WireDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
ZacksWhy Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
